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Abstract
Background: Several studies have shown that serum IL-10, IFNγ and MIF are elevated in patients in severe dengue
(SD) and could be used as potential biomarkers. We proceeded to determine if these cytokines could be used as
biomarkers in a large cohort of adult dengue patients with varying severity of dengue infection.
Methods: Serum IL-10 levels were determined in 259 of whom 40 had severe dengue infection. Serum IFNγ and
IFNα levels were done in 78 and MIF levels were done in 65 patients with acute dengue infection. Clinical features
and laboratory investigations were undertaken during the febrile and critical phase.
Results: We found that serum IL-10 levels were significantly higher (p = 0.001) in patients with SD, when compared
to those with non SD. Serum IL-10 levels significantly and inversely correlated with white cell counts (R = −0.23,
p = 0.0002) and lymphocyte counts (R = −0.29, p < 0.0001) but significantly and positively correlated with aspartate
tranaminase levels (R = 0.16, p = 0.01) and alanine transaminase levels (R = 0.22, p = 0.007). However, IL-10 levels did
not have a good predictive value in discriminating those who were likely to develop SD (AUC = 0.66). Serum IFNγ
levels were also significantly higher (p = 0.04) in patients with SD when compared to non SD. There was no
difference (p = 0.34) in serum IFNα levels and serum MIF levels (p = 0.15) in patients with SD and non SD.
Conclusion: Although serum IL-10 was significantly elevated in patients with SD it had a poor discriminatory value
in identifying those with SD and non SD and therefore, is unsuitable to be used as a robust biomarker in this
cohort.
Background
Dengue viral infections have become one of the most
important mosquito borne viral infections in the world
with a 30-fold increase incidence. It has caused signifi-
cant outbreaks in five of six World Health Organization
(WHO) regions. It is estimated that 2.1 million cases of
dengue haemorrhagic fever (DHF)/dengue shock syn-
drome (DSS) occur every year [1]. Sri Lanka has had
several annual dengue epidemics for the past 21 years,
and the incidence and severity of these epidemics is in-
creasing [2].
Although most individuals infected with the dengue
virus experience asymptomatic or mild febrile illness,
some develop dengue haemorrhagic fever (DHF) or
shock (DSS) which can be fatal. Case fatalities due to
dengue infection are around 1-5% depending on the
country and epidemic [3]. Early detection of shock and
other complications and supportive therapy has shown
to reduce the morbidity and mortality [3-5]. Dengue
infections predominantly affect developing countries
which have scarce resources to handle large numbers of
patients who are admitted to wards during periods of
epidemics. Therefore, early identification of patients who
are likely to develop severe disease and complications
would enable clinicians to act quickly in order to
minimize severe disease.
Clinical features in dengue infection occur abruptly
and are often described according to three phases- the
febrile phase, critical phase and the convalescent phase.
Severe clinical disease manifestations such as fluid leak-
age, bleeding and shock are seen during the critical
phase which begins around day 4–7 of the illness and
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usually lasts 48–72 hours [3]. However, not all patients
who are in the febrile phase proceed to the critical phase
and some proceed directly to the convalescent phase.
An ideal biomarker should be able to identify which
patients are likely to develop severe clinical disease man-
ifestations, before they develop bleeding, fluid leakage or
shock.
Several groups have tried to identify cytokine and
other laboratory profiles in patients with varying severity
of dengue infection, in order to determine which of
these could be used as predictors for development of se-
vere clinical disease. In these studies, IL-1ß, IFN-γ, IL-4,
IL-6, IL-13, IL-7, GM-CSF (Granulocyte-macrophage
colony-stimulating factor), MIF (macrophage migration
inhibitory factor), IL-10 along with several other cyto-
kines have been found to be elevated in patients with
DHF when compared to dengue fever (DF) [6-10]. Some
have shown that MIF, IL-10, IL-6, MIP-1ß and IFNγ
could be used as potential predictors of severe dengue
[6,9]. As dengue infections are very dynamic, more re-
cent studies have investigated serial changes in cytokine
patterns in patients with acute dengue infection. A re-
cent very carefully conducted study in 44 adult patients
with dengue fever DF and 18 patients with DHF has
showed that cytokines such as IFNγ, IL-17, IL-4, IL-1β
and vascular endothelial growth factor (VEGF) were sig-
nificantly higher in patients with DF when compared to
those with DHF in the febrile phase [10]. In this study
where all patients had primary dengue, all cytokine
levels were higher in patients with DF when compared
to those with DHF. Similar studies conducted in a larger
group of children with DF and DHF have shown that
serum IL-10 levels rose at defervescence only in those
who progressed to DSS [11]. Other longitudinal studies
have also shown that serum IL-10 levels increased dur-
ing defervescence in dengue patients with warning signs,
but IL-10 levels fell in those with no warning signs [12].
As our previous studies have shown that IL-10 was
associated with T cell apoptosis [13] and many other
studies have shown that serum IL-10, IFNγ and MIF
levels were higher in patients with severe dengue we
proceeded to investigate the use of these cytokines as
potential biomarkers to predict those who are likely to




259 adult patients with clinical features suggestive of
dengue infection who were admitted to a general med-
ical ward in two tertiary care hospitals in Colombo
during the year 2011, were enrolled in the study fol-
lowing informed written consent. Blood samples were
also obtained from 15 healthy volunteers to determine
serum cytokine levels in the population. The study
was approved by the Ethical Review Committee of the
University of Sri Jayawardanapura. The initial blood
sample was obtained during day 4 and 5 of illness
(day 1 was considered as first day of fever). A second
blood sample was obtained in 65/259 patients during
the critical phase (2 days after obtaining the first
blood sample) in those who gave consent. Clinical
features such the presence of dengue warning signs,
blood pressure, pulse rate and volume, general status
of the patient, presence of any bleeding manifesta-
tions and presence of any possible fluid accumulation
in the pleural cavity and abdomen were monitored
several times a day from the time of admission to
hospital, until they were discharged. Laboratory inves-
tigations such as the full blood counts were done several
times a day in all patients until they were discharged from
hospital. Serum electrolytes, coagulation profiles, chest
radiography and ultrasound scans of the abdomen were
only done in selected patients due to resource limitations.
The patients were classified as having severe dengue
according to the 2009 WHO guidelines [3]. Based on the
2009 WHO diagnostic criteria, shock was defined as
lowering of pulse pressure to 20 mmHg or less or the
presence of signs of poor capillary perfusion (cold ex-
tremities, poor capillary refill or a rapid pulse rate)
[3]. Patients were classified as having severe dengue if
they developed signs of shock, developed severe bleeding
or had features of organ impairment such as liver trans-
aminases exceeding 1000/IU.
Serology
Acute dengue infection was confirmed by testing the
serum samples with a commercial capture-IgM and IgG
enzyme-linked immunosorbent assay (ELISA) (Panbio,
Brisbane, Australia). The ELISA was performed and the
results were interpreted according to the manufacturer’s
instructions. This ELISA assay has been validated as
both sensitive and specific for primary and secondary
dengue virus infections [14,15].
Quantitative cytokine assays
Quantitative cytokine assays were done in duplicate on
serum samples obtained on 4–5 of illness. Serum IL-10
levels (Mabtech, Sweden) were done in all serum samples
and were also done in all the serum samples obtained dur-
ing the critical phase using IL-10 pre-coated ELISA plates
according to the manufacturer’s instructions. Serum IFNγ
levels (Mabtech, Sweden) and IFNα levels (Mabtech,
Sweden) were only done in duplicate in 78 patients in the
samples obtained on the date of admission and these as-
says were again performed using precoated IFNγ ELISA
plates and precoated IFNα ELISA plates according to the
manufacturer’s instructions. Serum MIF levels (Biolegend,
Malavige et al. BMC Infectious Diseases 2013, 13:341 Page 2 of 7
http://www.biomedcentral.com/1471-2334/13/341
USA) were done in duplicate in paired serum samples
obtained on the date of admission and the critical phase
(2 days after obtaining the first blood sample) using MIF
pre-coated ELISA plates according to the manufacturer’s
instructions.
Statistical analysis
Statistical analysis was performed using Graph pad
PRISM version 6. As the data were not normally distrib-
uted, differences in means were compared using the
Mann–Whitney U test (two tailed). Degree of associ-
ation between clinical parameters and serum cytokine
levels were done using Spearmans correlation. Receiver-
operator characteristic (ROC) curves showing the area
under the curve (AUC) were generated to determine
the discriminatory performance of serum IL-10 levels,
platelet counts, lymphocyte counts and liver trans-
aminase levels.
Results
Of the 259 patients, 40 (15.4%) patients were classified
as having severe dengue. Their mean age was 26.8 years
(SD ± 11.9). 72 (27.8%) had abdominal pain, 100 (38.6%)
had vomiting, 37 (14.3%) had pleural effusions, 7 (2.7%)
had ascites and 17 (6.6%) developed bleeding manifesta-
tions. However, none of the patients developed severe
bleeding. Based on the presence of dengue specific IgM
antibodies in the absence of IgG antibodies, 50 (19.3%)
patients were found to have primary dengue infection.
Association of serum IL-10 with disease severity
Patients with severe dengue had significantly lower white
cell counts and platelet counts and significantly higher
alanine transaminase levels and aspartate transaminase
levels than those with non severe dengue (Table 1).
Serum IL-10 levels were significantly higher (p = 0.001)
in patients with severe dengue (mean 291.6 ± SD 573.6,
median 154.3, range 24.98 to 3271 pg/ml), when com-
pared to those with non severe dengue (mean 156.6 ± SD
258.2, median 81.9, range 7.8 to 2681 pg/ml) (Figure 1A).
Serum IL-10 levels significantly and inversely correlated
with white cell counts (Spearmans R = −0.23, p = 0.0002)
and lymphocyte counts (Spearmans R = −0.29, p < 0.0001).
Serum IL-10 levels significantly and positively correlated
with the highest aspartate tranaminase (AST) levels
(Spearmans R = 0.16, p = 0.01) and the highest alanine
transaminase (ALT) levels (Spearmans R = 0.22, p = 0.007)
but not with the lowest platelet count in the critical phase
(Table 2).
Serum IL-10 levels in the febrile phase, very signifi-
cantly and positively correlated with serum IFNγ levels
(Spearmans R = 0.55, p < 0.0001) and IFNα levels
(Spearmans R = 0.3, p = 0.04) in the febrile phase. Serum
IL-10 and MIF levels were determined in 65 patients
(7 of them with severe dengue) in both the febrile
phase and the critical phase. Serum IL-10 levels rose
in 17/65 of these patients, while serum IL-10 levels
fell in the other 48 patients (Figure 1B). Of the 17
patients in which the serum IL-10 levels rose, 5 had
severe dengue. There was no difference in other parame-
ters such as platelet counts, white cell counts and liver
transaminases in patients in whom the IL-10 levels rose in
the second sample when compared to other patients.
However, serum IL-10 levels in the critical phase were
again significantly higher (p = 0.01), in patients with SD
(mean 323.1, SD ± 331.9, median 214.2, range 71.82 to
1036 pg/ml) when compared to those with non SD (mean
147.3, SD ± 217.5, median 87.9, range 20.5 to 1508 pg/ml).
Serum IL-10 levels in the febrile phase significantly and
positively correlated with the paired IL-10 levels in the
critical phase (Spearmans R = 0.67, p < 0.0001). Although
the serum IL-10 levels in the febrile phase did not correl-
ate with MIF levels in the febrile phase, they negatively
correlated with serum MIF levels observed in the critical
phase (Spearmans R = −0.47, p = 0.01) (Table 3).
Association of other cytokines with disease severity
Serum IFNγ levels were also significantly higher (p = 0.04)
in patients with severe dengue (mean 268.8, SD ± 346.2,
median 128.4, range 29.8 to 1405 pg/ml) when compared
Table 1 Laboratory parameters in patients with severe and non severe dengue
Clinical characteristic Severe dengue N = 40 Non severe dengue N = 219 P
valueMean (±SD) Mean (±SD)
Day of illness when admitted to hospital 4.8 (±1.2) 5.25 (±1.6) 0.17
Age (years) 23.3 (8.8) 27.4 (11.4) 0.03
Lowest white cell count (cells/mm3) 2761 (±1406) 3434 (±2103) 0.059
Lowest lymphocyte count (cells/mm3) 1060 (±579) 1507 (±1230) 0.06
Lowest platelet count (cells/mm3) 29,949 (±26,335) 47,229 (±33,691) 0.0004
Alanine transaminase levels 213.8 (±279.9) 87.03 (±95.05) 0.001
Aspartate transaminase levels 474.6 (±893.2) 169.9 (±154.4) 0.0001
Serum IL-10 levels pg/ml 291.6 (±573.8) 183.4 (±472.8) 0.001
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to non severe dengue (mean 174, SD ± 265.6, median 72.2,
range 8.1 to 1466 pg/ml). (Figure 2A). Serum IFNγ levels
significantly and negatively correlated with white cell
counts (Spearmans R = −0.37, p = 0.001) and lymphocyte
counts (Spearmans R −0.44, p = 0.0001). However, no as-
sociation was seen with liver transaminases or platelet
counts. There was no difference (p = 0.34) in serum IFNα
levels in patients with SD (mean 102, SD ± 201, median
26.14, range 12.37 to 838.2 pg/ml) and non SD (mean
83.33, SD ± 167.4, median 25, range 8.9 to 960.1 pg/ml)
(Figure 2A). However, as seen with serum IL-10 and IFNγ
levels a significant and negative correlation was observed
with serum IFNα levels and white cell counts and lympho-
cyte counts.
Serum MIF levels were done in 65 paired serum sam-
ples. Serum MIF levels were higher in patients with se-
vere dengue (mean 69,007, SD ± 58,692, median 48,044,
range 12,685 to 200,000 pg/ml) when compared to those
with non severe dengue (mean 39,783, SD ± 26,139, me-
dian 28,932, range 3908 to 102,589 pg/ml) although this
was not statistically significant (p = 0.15) (Figure 2B).
Serum cytokines in primary vs secondary dengue
50 of our patients had a primary dengue infection
whereas 209 had a secondary dengue infection. IL-10
levels were significantly higher (p = 0.01) in those with
primary dengue (mean 363, SD ± 923.6 pg/ml) than those
with secondary dengue (mean 161.1, SD ± 298.6 pg/ml).
In primary dengue infection serum IL-10 was slightly
lower in the febrile phase (mean 135.8, SD ± 129.7 pg/ml)
when compared to the critical phase (mean 154. 2,
SD ± 183.2 pg/ml) although not statistically significant.
On the other hand, serum IL-10 levels slightly de-
creased in the critical phase in those with secondary
dengue infection (168.3, SD ± 243.7 pg.ml) when com-
pared to the febrile phase (mean 198.1, SD ± 293.7 pg/ml)
(Figure 3A). There was no difference in the IL-10
levels in patients with primary dengue who had se-
vere dengue (mean 162.1, SD ± 103.5 pg/ml) when com-
pared to those with non severe dengue (mean 194.2,
SD ± 151.1 pg/ml). However, serum IL-10 was higher
in patients with severe secondary dengue infection
Figure 1 Serum IL-10 levels and clinical diseases severity. A:
Serum IL-10 levels in patients with severe dengue (n = 40), non
severe dengue (n = 219) and healthy controls (n = 11). B: Serum
IL-10 levels in patients with severe dengue (SD) (n = 7) and non
severe dengue (n = 57) in the febrile phase and the critical phase.
C: ROC curves of serum IL-10 levels (n-259).
Table 2 Correlation of laboratory parameters with serum
IL-10 levels in the febrile phase
Laboratory parameters Spearmans R value P value
Lowest lymphocyte count −0.23 0.0002
Lowest white cell count −0.29 <0.0001
Lowest platelet count 0.03 0.55
Aspartate transaminase levels 0.16 0.02
Alanine transaminase levels 0.22 0.0007
Table 3 Correlation of serum IL-10 levels in the febrile
phase with other serum cytokines
Cytokine Spearmans R value P value
Serum IL-10 levels in the critical phase 0.67 <0.0001
Serum MIF levels in the febrile phase 0.06 0.61
Serum MIF levels in the critical phase −0.47 0.01
Serum IFNγ levels in the febrile phase 0.55 <0.0001
Serum IFNα levels in the febrile phase 0.29 0.04
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(mean 329.1, SD ± 647.1 pg/ml) when compared to those
with non severe dengue (mean 164, SD ± 155.1 pg/ml)
(data not shown). Serum IFNγ levels were significantly
higher (p = 0.007) in patients with primary dengue (mean
361.6, SD ± 399.6) when compared to those with second-
ary dengue infection (mean 161, SD ± 246.3) (Figure 3B).
No such difference was seen in serum IFNα levels
(p = 0.31). In contrast, serum MIF levels were significantly
higher (p = 0.007) in patients with secondary dengue
(mean 115,276, SD ± 538,567) when compared to those
with primary dengue (mean 12669, SD ± 8.240).
Usefulness of serum IL-10 levels in the febrile phase as a
potential biomarker
Although serum IL-10 levels were found to be associated
with severe clinical disease and also significantly correlated
with other parameters of severe clinical disease such as
liver transaminases, IL-10 levels did not have a good pre-
dictive value in discriminating those who were likely to de-
velop severe disease (AUC= 0.66) (Figure 1C). When using
the IL-10 cut-off value as 115.8 pg/ml (mean + 2SD of the
serum IL-10 values in healthy controls), the odds ratio of
developing severe dengue was 2.77 (95% CI 1.386 to
5.520). At the cut-off value of 115.86 pg/ml the specificity
was 89.9%, but the sensitivity was only 23.8% indicating
that serum IL-10 values are not suitable to be used as a ro-
bust biomarker in this population.
Discussion
We have attempted to determine if cytokines such as
IL-10, IFNγ and MIF, which were suggested as poten-
tial biomarkers by others, could be used as biomarkers in
a large cohort of patients with acute dengue infection in
Figure 2 Association of serum interferon and MIF levels with
clinical disease severity. A: Serum IFNγ in patients with severe
dengue (n = 20) and non severe dengue (n = 58) and IFNα levels in
patients with severe dengue (SD) (n = 20) and non SD dengue in
the febrile phase (n = 58). B: Serum MIF levels in patients with severe
dengue (SD) (n = 7) and non severe dengue (n = 57) in the febrile
phase and the critical phase.
Figure 3 Serum cytokine levels in primary and secondary
dengue infection. A: Serum IL-10 levels in patients with primary
(n = 9) and secondary dengue (n = 56) in the febrile phase and the
critical phase. B: Serum IFNγ and serum IFNα levels in primary
(n = 15) and secondary dengue (n = 63).
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Sri Lanka [9,11,12]. We obtained the first blood sample
from patients on 4 to 5 day of illness as adult individuals
with suspected dengue infection rarely seek medical treat-
ment before this. We found that serum IL-10 levels indeed
were significantly higher in patients with severe dengue
and also significantly associated with other disease severity
markers such as liver transaminase levels. Serum IL-10
has also been shown to be associated with severe disease
in other acute viral infections such as influenza [16].
Although many studies carried out in relatively small
patient groups have suggested that IL-10 could possibly
be used as a biomarker to predict severe clinical disease
[6,17,18], we found that serum IL-10 alone did not have
a good discriminatory value (AUC = 0.66). A recent
study in 52 patients with acute dengue infection (which
included 3 patients with severe dengue) has shown that
serum IL-10 levels along with platelet counts were two
of the most important parameters associated with DHF
[17]. However, when validating the use of serum IL-10
in a larger population of dengue patients, we found that
serum IL-10 is unlikely to be useful as a biomarker be-
cause of its variability. For instance, when we used the
serum IL-10 cut-off value as 115.8 pg/ml (mean + 2SD
of the serum IL-10 values in healthy controls), 15 pa-
tients with SD had values less than this value. We feel
that the wide range of IL-10 and other cytokines seen in
patients with severe dengue and milder forms of dengue
is due to the complex nature of this disease. Although
the critical phase has shown to be associated with rising
of the haematocrit, reduction of platelet counts along
with clinical fluid accumulation, the exact time the
patient enters the critical phase may be sometimes
difficult to determine with these clinical parameters
alone. Furthermore, the probability of a patient devel-
oping shock would also depend on the fluid manage-
ment regime and how well the patient is monitored.
Therefore, there are many confounding factors when
trying to use cytokines to determine progression to
severe dengue.
As dengue is a very dynamic disease, we determined
serum IL-10 levels and MIF levels in 65 patients during
the febrile phase and critical phase, hoping to gain a bet-
ter insight into how these cytokines change in patients
with SD and non SD. Of these 65 patients, serum IL-10
levels rose in the second sample in 17 patients, while in
48 patients the IL-10 levels fell. The serum MIF levels
did not follow the same pattern as in some patients who
had an increase in serum IL-10 in the second sample,
MIF levels fell and vice versa. Furthermore, the patients
in whom serum IL-10 levels rose did not have more se-
vere clinical disease than those who had decreasing
serum IL-10 levels. However, similar to the observations
in the febrile phase, serum IL-10 levels in the critical
phase was associated with SD (p = 0.01). However, we
believe that obtaining samples on just 2 days in acute
dengue infection would be unsuitable to determine pos-
sible biomarkers as it is a very dynamic disease. Al-
though we obtained the first sample on day 4–5 of
illness, this time point might still be too late in the ill-
ness to identify potential biomarkers to predict severe
disease. In addition, as investigations such as serial ultra
sound imaging of the abdomen could not be done due
to limited resources there is a possibility that the severity
was not identified correctly in all patients. A recent
study by Rathnakrishnan et al., which investigated cyto-
kine and chemokine patterns in three phases of dengue
showed that marked differences in cytokine levels were
seen based on the phase of dengue infection [12]. They
found that MIP-1β and IP-10 levels were overall higher
in the febrile and critical phases of dengue and serum
IL-10 levels remained unchanged in patients with den-
gue with warning signs, whereas levels decreased in
those without warning signs [12]. Therefore, their data
too appears to support that IL-10 appears to have a role
in the pathogenesis of dengue.
However, since in our previous studies [13] and several
others have shown that IL-10 is associated with severe
clinical disease, it would be crucial to determine the role
of IL-10 in the pathogenesis of dengue infections.
We found that serum IL-10 levels significantly corre-
lated with both ALT and AST levels and the association
was stronger with serum ALT levels. AST and ALT are
both considered as liver transaminases and they are re-
leased from hepatocytes. ALT is considered as a more
specific marker of liver inflammation than AST, as AST
is also released from other sites including skeletal mus-
cles, heart, kidneys and brain. Therefore, since the cor-
relation of serum IL-10 levels was more with ALT than
with AST, it appears that it is more likely to be associ-
ated with liver inflammation. Therefore, association of
serum IL-10 with ALT may signify liver injury and the
rise in IL-10 could be possibly secondary to liver inflam-
mation and be protective.
Conclusions
In summary, we have determined whether serum IL-10
and several other cytokines could be used as potential
biomarkers to predict severe dengue infection, in a large
cohort of patients with a varying severity of acute den-
gue infection. We found that serum IL-10 and IFNγ
were significantly elevated in patients with severe den-
gue. Serum IL-10 levels positively and significantly cor-
related with liver transaminases and inversely correlated
with white cell counts and lymphocyte counts. However,
serum IL-10 had a poor discriminatory value in identify-
ing those with severe dengue and non severe dengue
and therefore, is unlikely to be useful as a robust bio-
marker in this population.
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